they are a cancer drug developer, and has no product so far, but again it have every thing to do with the EXPECTATION OF THE COMPANY'S FUTURE EARNINGS
PV1 Provaris tells ASX non-binding MOUs are still material to share prices in somewhat fiery compliance response